Lymphomas | Clinical

Behind the FDA Approval: Liso-Cel for R/R Large B-Cell Lymphoma

June 30, 2022

In an interview with Targeted Oncology, Manali Kamdar, discussed the recent FDA approval of lisocabtagene maraleucel for the treatment of patients with relapsed or refractory large B-cell lymphoma, and how community oncologists should approach patient referrals and post-treatment care.

Positive Outcomes of Novel Cellular Therapies Are Seen in Long Relapse, DLBCL

June 17, 2022

Patients with relapsed/refractory diffuse large B-cell lymphoma who benefit most from novel therapies vs patients who would likely do well with standard treatment were identified among all curatively treated patients in Sweden from 2007 to 2014.